|

Risvutatug rezetecan Clinical Trials

1 actively recruiting trial across 1 location

Also known as: GSK5764227, HS-20093

Pipeline

Early 1: 1

Top Sponsors

  • Nader Sanai1

Indications

  • Brain Metastasases1
  • Glioblastoma (GBM)1
  • Cancer1

Phoenix, Arizona1 trial

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

St. Joseph's Hospital and Medical Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.